Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Phase I Dose-escalation and Dose-expansion Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors

NCT05344742 is registered in ClinicalTrials.gov with CSPC ZhongQi Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT05344742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05344742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Phase I Dose-escalation and Dose-expansion Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors
Lead sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
April 30, 2022
Completion date
March 31, 2025
Enrollment
116 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor